Table 1.
Subject characteristics by randomized group at baseline and after interventions. Data shown are mean (SD), median (interquartile range), or n (%). RM-ANOVA revealed no statistically significant differences for group-by-time interaction.
| Allopurinol (n=30) |
Losartan (n=28) |
Placebo (n=28) | P-value* | P-value¶ | |
|---|---|---|---|---|---|
| Sex (female) | 10 (33%) | 15 (54%) | 9 (32%) | 0.180 | ----- |
|
| |||||
| Age (yr) | 49 (8) | 49 (12) | 47 (9) | 0.677 | ----- |
|
| |||||
| Body mass index (kg/m2) | |||||
| Initial | 38.2 (7.2) | 38.6 (7.4) | 34.5 (6.6) | 0.061 | |
| Final | 38.6 (7.1) | 39.1 (7.6) | 34.8 (6.4) | 0.062 | 0.579 |
|
| |||||
| Height (m) | |||||
| Initial | 1.74 (0.10) | 1.74 (0.11) | 1.73 (0.11) | 0.851 | |
| Final | 1.74 (0.10) | 1.74 (0.10) | 1.73 (0.11) | 0.893 | 0.952 |
|
| |||||
| Weight (kg) | |||||
| Initial | 116.6 (26.4) | 118.5 (30.4) | 103.3 (22.5) | 0.071 | |
| Final | 117.2 (25.6) | 119.5 (30.7) | 103.9 (21.8) | 0.078 | 0.504 |
|
| |||||
| Apnoea-hypopnoea index (events/hr) | |||||
| 33 (24-50) | 46 (27-58) | 35 (18-59) | 0.653 | ||
| 45 (22-68) | 44 (25-67) | 26 (15-62) | 0.358 | 0.070 | |
|
| |||||
| Respiratory distress index (events/hr) | |||||
| Initial | 37 (25-51) | 49 (27-60) | 42 (24-61) | 0.734 | |
| Final | 50 (22-69) | 50 (25-67) | 31 (20-64) | 0.445 | 0.074 |
|
| |||||
| Time <88% SaO2 (%) | |||||
| Initial | 5 (1-15) | 10 (4-25) | 5 (1-9) | 0.208 | |
| Final | 8 (2-18) | 12 (2-35) | 3 (1-8) | 0.097 | 0.269 |
|
| |||||
| Fasting blood glucose (mg/dL) | |||||
| Initial | 94 (15) | 96 (10) | 91 (10) | 0.330 | |
| Final | † | † | † | ----- | |
|
| |||||
| Triglycerides (mg/dL) | |||||
| Initial | 145 (56) | 150 (49) | 139 (62) | 0.759 | |
| Final | † | † | † | ----- | |
†
post-intervention measurements not obtained (these were inclusion criteria)
*
P-value for between-group comparison at each time point
¶
P-value for group-by-time interaction, adjusted for average daily CPAP use (min)